Iurisci I - Search Results

1

Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis.

Rabinovich GA, Cumashi A, Bianco GA, Ciavardelli D, Iurisci I, D'Egidio M, Piccolo E, Tinari N, Nifantiev N, Iacobelli S. Rabinovich GA, et al. Among authors: iurisci i. Glycobiology. 2006 Mar;16(3):210-20. doi: 10.1093/glycob/cwj056. Epub 2005 Nov 10. Glycobiology. 2006. PMID: 16282605

2

Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis.

Iurisci I, Cumashi A, Sherman AA, Tsvetkov YE, Tinari N, Piccolo E, D'Egidio M, Adamo V, Natoli C, Rabinovich GA, Iacobelli S, Nifantiev NE; Consorzio Interuniversitario Nazionale Per la Bio-Oncologia. Iurisci I, et al. Anticancer Res. 2009 Jan;29(1):403-10. Anticancer Res. 2009. PMID: 19331179 Free article.

3

90K (Mac-2 BP) and galectins in tumor progression and metastasis.

Grassadonia A, Tinari N, Iurisci I, Piccolo E, Cumashi A, Innominato P, D'Egidio M, Natoli C, Piantelli M, Iacobelli S. Grassadonia A, et al. Among authors: iurisci i. Glycoconj J. 2002;19(7-9):551-6. doi: 10.1023/B:GLYC.0000014085.00706.d4. Glycoconj J. 2002. PMID: 14758079 Review.

4

Concentrations of galectin-3 in the sera of normal controls and cancer patients.

Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S. Iurisci I, et al. Clin Cancer Res. 2000 Apr;6(4):1389-93. Clin Cancer Res. 2000. PMID: 10778968

5

Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer.

Iurisci I, Rich T, Lévi F, Innominato PF, Tinari N, Irtelli L, De Tursi M, Grassadonia A, Iacobelli S. Iurisci I, et al. J Clin Oncol. 2007 Jun 1;25(16):e17-9. doi: 10.1200/JCO.2007.11.3274. J Clin Oncol. 2007. PMID: 17538154 No abstract available.

6

Immunohistochemical and serological 90K/Mac-2BP detection in hepatocellular carcinoma patients: different behaviour of two monoclonal antibodies.

Valentini AM, Iacovazzi PA, Correale M, Pirrelli M, Armentano R, Iacobelli S, Tinari N, Iurisci I, Caruso ML. Valentini AM, et al. Among authors: iurisci i. Med Chem. 2005 Mar;1(2):185-9. doi: 10.2174/1573406053175229. Med Chem. 2005. PMID: 16787313

7

Liver circadian clock, a pharmacologic target of cyclin-dependent kinase inhibitor seliciclib.

Iurisci I, Filipski E, Sallam H, Harper F, Guettier C, Maire I, Hassan M, Iacobelli S, Lévi F. Iurisci I, et al. Chronobiol Int. 2009 Aug;26(6):1169-88. doi: 10.3109/07420520903209942. Chronobiol Int. 2009. PMID: 19731111

8

Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor.

Iurisci I, Filipski E, Reinhardt J, Bach S, Gianella-Borradori A, Iacobelli S, Meijer L, Lévi F. Iurisci I, et al. Cancer Res. 2006 Nov 15;66(22):10720-8. doi: 10.1158/0008-5472.CAN-06-2086. Cancer Res. 2006. PMID: 17108108

9

Cross-talks between circadian timing system and cell division cycle determine cancer biology and therapeutics.

Lévi F, Filipski E, Iurisci I, Li XM, Innominato P. Lévi F, et al. Among authors: iurisci i. Cold Spring Harb Symp Quant Biol. 2007;72:465-75. doi: 10.1101/sqb.2007.72.030. Cold Spring Harb Symp Quant Biol. 2007. PMID: 18419306 Review.

10

[Dynamic circadian system patients under chimiotherapy].

Beau J, Iurisci I, Beau T, Lévi F. Beau J, et al. Among authors: iurisci i. Pathol Biol (Paris). 2007 Apr-May;55(3-4):171-5. doi: 10.1016/j.patbio.2006.12.004. Epub 2007 Apr 6. Pathol Biol (Paris). 2007. PMID: 17412521 French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

14 results

Search Page